Hepatitis C Therapy

FDA approves drug combination as first hepatitis C treatment for HIV patients

Published in Hepatitis Weekly, March 28th, 2005

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) for the treatment of chronic hepatitis C in patients co-infected with hepatitis C and HIV.

This Pegasys combination therapy is effective in leading to a sustained virological response (SVR, indicative of a cure), providing a compelling reason to consider treatment in this previously undertreated patient group. Pegasys combination therapy is the only regimen approved in the U.S. for hepatitis C treatment in patients with HIV. Hepatitis C has become the most frequent cause of liver disease in HIV patients, and in some regions, may...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry